Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia

Annals of Hematology

Volumn 92, Issue 8, 2013, Pages 1079-1090

  Rickmann, Mareike ^a   Macke, Laura ^a   Sundarasetty, Bala Sai ^a   Stamer, Kathrin ^a   Figueiredo, Constanca ^a   Blasczyk, Rainer ^a   Heuser, Michael ^a   Krauter, Juergen ^a   Ganser, Arnold ^a   Stripecke, Renata ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Dendritic cell; Immune monitoring; Inflammatory cytokines; Leukemia; Myeloid derived suppressor cells; Risk of relapse

Indexed keywords

CD123 ANTIGEN; CD135 ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CYTOKINE; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; NUCLEOPHOSMIN; TUMOR NECROSIS FACTOR ALPHA; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTIGEN DETECTION; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CYTOGENETICS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; PRIORITY JOURNAL; STEM CELL; SUPERNATANT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, DIFFERENTIATION; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CULTURE MEDIA, CONDITIONED; CYTOKINES; DENDRITIC CELLS; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENES, WILMS TUMOR; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MONOCYTES; MYELOID CELLS; NEOPLASM, RESIDUAL; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TANDEM REPEAT SEQUENCES;

EID: 84880283502     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1744-y     Document Type: Article

References (46)

1. Estey EH (2012) Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87(1):89-99. doi: 10.1002/ajh.22246
2. Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J, Caron D, Lebsack ME, McKenna HJ (2000) In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96(3):878-884
3. Li L, Piloto O, Kim KT, Ye Z, Nguyen HB, Yu X, Levis M, Cheng L, Small D (2007) FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. Br J Haematol 137(1):64-75. doi: 10.1111/j.1365-2141.2007.06525.x
4. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DC (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111(5):2776-2784. doi: 10.1182/blood-2007-08- 109090
5. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Dohner H (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358(18):1909-1918. doi: 10.1056/NEJMoa074306
6. Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B, Ganser A (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108(12):3898-3905. doi: 10.1182/blood-2006-04-014845
7. Marcucci G, Haferlach T, Dohner H (2011) Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 29(5):475-486. doi: 10.1200/JCO.2010.30.2554
8. Thol F, Kolking B, Damm F, Reinhardt K, Klusmann JH, Reinhardt D, von Neuhoff N, Brugman MH, Schlegelberger B, Suerbaum S, Krauter J, Ganser A, Heuser M (2012) Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Gene Chromosome Cancer. doi: 10.1002/gcc.21955
9. Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G, Iori AP, Verdonck LF, Volin L, Gratwohl A, Sierra J, Mohty M, Rocha V (2012) Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 30(7):735-741. doi: 10.1200/JCO.2011.36.9868
10. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ (2012) Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 119(14):3256-3262. doi: 10.1182/blood-2011-09-380386
11. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392(6673):245-252. doi: 10.1038/32588
12. Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12(4):265-277. doi: 10.1038/nrc3258
13. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6(5):1755-1766
14. Rickmann M, Krauter J, Stamer K, Heuser M, Salguero G, Mischak-Weissinger E, Ganser A, Stripecke R (2011) Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Ann Hematol. doi: 10.1007/s00277-011-1231-2
15. Elenkov IJ, Chrousos GP (1999) Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol Metab TEM 10(9):359-368
16. Elenkov IJ, Chrousos GP (2002) Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 966:290-303
17. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR (2011) Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 51(2-3):170-182. doi: 10.1007/s12026-011-8262-6
18. Mossner R, Mikova O, Koutsilieri E, Saoud M, Ehlis AC, Muller N, Fallgatter AJ, Riederer P (2007) Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry 8(3):141-174. doi: 10.1080/15622970701263303
19. Multhoff G, Molls M, Radons J (2011) Chronic inflammation in cancer development. Front Immunol 2:98. doi: 10.3389/fimmu.2011.00098
20. Wu H, Li P, Shao N, Ma J, Ji M, Sun X, Ma D, Ji C (2012) Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-beta in acute myeloid leukemia. Oncol Lett 3(5):1119-1123. doi: 10.3892/ol.2012.614
21. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Dohner H, Dohner K (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100(13):4372-4380. doi: 10.1182/blood-2002-05-1440
22. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, Schnittger S (2005) Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19(8):1416-1423. doi: 10.1038/sj.leu.2403809
23. Mosser DM, Zhang X (2008) Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226:205-218. doi: 10.1111/j.1600-065X.2008.00706.x
24. Burger D, Dayer JM (2002) Cytokines, acute-phase proteins, and hormones: IL-1 and TNF-alpha production in contact-mediated activation of monocytes by T lymphocytes. Ann N Y Acad Sci 966:464-473
25. Talarn C, Urbano-Ispizua A, Martino R, Perez-Simon JA, Batlle M, Herrera C, Granell M, Gaya A, Torrebadell M, Fernandez-Aviles F, Aymerich M, Marin P, Sierra J, Montserrat E (2007) Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome. Haematologica 92(12):1655-1663. doi: 10.3324/haematol.11076
26. Porta MD, Rigolin GM, Alessandrino EP, Maiocchi M, Malcovati L, Vanelli L, Barate C, Rumi E, Ciccone M, Cuneo A, Lazzarino M, Castoldi G (2004) Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. Eur J Haematol 72(1):18-25. doi: 10.1046/j.0902-4441.2004.00172.x
27. Condamine T, Gabrilovich DI (2011) Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 32(1):19-25. doi: 10.1016/j.it.2010.10.002
28. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI (2010) Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 184(6):3106-3116. doi: 10.4049/jimmunol.0902661
29. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, Roth J, Gabrilovich DI (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205(10):2235-2249. doi: 10.1084/jem.20080132
30. Motta JM, Nascimento CR, Rumjanek VM (2010) Leukemic cell products down-regulate human dendritic cell differentiation. Cancer Immunol Immunother 59(11):1645-1653. doi: 10.1007/s00262-010-0890-5
31. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166(1):678-689
32. Pinzon-Charry A, Maxwell T, Lopez JA (2005) Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 83(5):451-461. doi: 10.1111/j.1440-1711.2005.01371.x
33. Ara T, Declerck YA (2010) Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46(7):1223-1231. doi: 10.1016/j.ejca.2010.02.026
34. Leung KN, Mak NK, Fung MC (2005) Cytokines in the differentiation therapy of leukemia: from laboratory investigations to clinical applications. Crit Rev Clin Lab Sci 42(5-6):473-514. doi: 10.1080/10408360500295154
35. Moller B, Villiger PM (2006) Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol 27(4):391-408. doi: 10.1007/s00281-006-0012-9
36. Multhoff G, Radons J (2012) Radiation, inflammation, and immune responses in cancer. Front Oncol 2:58. doi: 10.3389/fonc.2012.00058
37. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI (2009) Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 182(9):5693-5701. doi: 10.4049/jimmunol.0900092
38. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162-174. doi: 10.1038/nri2506
39. Filipazzi P, Huber V, Rivoltini L (2012) Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 61(2):255-263. doi: 10.1007/s00262-011-1161-9
40. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67(20):10019-10026. doi: 10.1158/0008-5472.CAN-07-2354
41. Mougiakakos D, Jitschin R, von Bahr L, Poschke I, Gary R, Sundberg B, Gerbitz A, Ljungman P, Le Blanc K (2012) Immunosuppressive CD14(+)HLA-DR(low/ neg) IDO(+) myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia. doi: 10.1038/leu.2012.215
42. Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, Shapiro P, Small D, Rassool F (2008) Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 111(6):3173-3182. doi: 10.1182/blood-2007-05-092510
43. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R (2008) The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 113(7):1605-1613. doi: 10.1002/cncr.23785
44. Liu Y, Li PK, Li C, Lin J (2010) Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem 285(35):27429-27439. doi: 10.1074/jbc.M110.142752
45. Ferretti E, Di Carlo E, Cocco C, Ribatti D, Sorrentino C, Ognio E, Montagna D, Pistoia V, Airoldi I (2010) Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett 133(2):99-105. doi: 10.1016/j.imlet.2010.08.002
46. de Mejia EG, Wang W, Dia VP (2010) Lunasin, with an arginine-glycine- aspartic acid motif, causes apoptosis to L1210 leukemia cells by activation of caspase-3. Mol Nutr Food Res 54(3):406-414. doi: 10.1002/mnfr.200900073